Publication Name	World Journal of Clinical Cases
Manuscript ID	59388
Country	France

Category	Oncology
Manuscript Type	Case Report
Article Title	Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssière and Xavier Durando
Funding Agency and Grant Number
Corresponding Author	Hugo Veyssière, N/A, N/A, Division de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand 63011, France. hugo.veyssiere@clermont.unicancer.fr
Key Words	Thymic epithelial carcinoma; Programmed death-ligand 1 negative; Pembrolizumab; Immune checkpoint; Metastasis; Case report
Core Tip	Thymic epithelial carcinomas are rare and have poor prognosis. The overall 5-year survival rate for patients with thymic carcinoma is about 30%–50%. We present the case of a 45-year-old Caucasian male who presented with hepatalgia and a cervical mass, and was diagnosed with programmed death-ligand 1-negative metastatic thymic carcinoma. The patient underwent pretreatment with platinum-based chemotherapy, after which pembrolizumab was administered as salvage therapy and complete metabolic response was achieved.
Citation	Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147

Received	2020-10-26 08:01
Peer-Review Started	2020-10-26 08:01
To Make the First Decision
Return for Revision	2020-11-03 00:14
Revised	2020-11-12 08:48
Second Decision	2020-11-17 12:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-11-21 05:41
Articles in Press	2020-11-21 05:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-01-06 01:37

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com